An ascending multiple dose study of the safety, pharmacokinetics, and pharmacodynamics of SCA-136 [vabicaserin] administered orally to healthy Japanese male subjects

Trial Profile

An ascending multiple dose study of the safety, pharmacokinetics, and pharmacodynamics of SCA-136 [vabicaserin] administered orally to healthy Japanese male subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2008

At a glance

  • Drugs Vabicaserin (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 23 Jan 2008 The expected completion date for this trial is now 1 Oct 2007.
    • 04 Dec 2007 Status changed from recruiting to completed.
    • 18 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top